A venture capital firm with offices in Canada is looking to participate in the Seed to Series B financings of early-stage companies with typical investments between USD 0.5 million and USD 5 million. The firm is currently operating out of its second fund in which it has made three investments after making thirteen investments out of its inaugural fund. The firm participates in equity investments including SAFEs and convertible notes. The firm invests primarily in companies based in Canada, the United States, Europe, and Israel.
The firm is primarily interested in investing in companies in the digital health sector but will also consider the medical and diagnostic devices sectors that have a digital component to them. The firm is open to all modalities within the digital health but requires that the technologies be patient facing or have a patient component. The firm will not consider investments in biotech or pharma but will consider digital therapeutics. The firm is phase agnostic and will invest in development as well as on the market technologies. The firm will only invest in Class I and Class II (510k) medical devices, avoiding Class III (PMA). The firm is disease agnostic and will consider companies across all indications but prefers that there is ample market size for the technology to be revenue generating.
The firm prefers to work with experienced management teams. The firm looks to invest in companies in which the founder has a significant stake in the business. The firm is an active and strategic investor and will take a board seat as determined by check size on a case-by-case basis. The firm will participate both as a lead and co-investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply